Product image of Mixtard 30 Penfill (Insulin Human) supplied by GNH India

Mixtard 30 Penfill

Active Ingredient:
Insulin Human
Origin:
EU

Mixtard 30 Penfill (Insulin Human)

Insulin human, the active ingredient in Mixtard 30 Penfill, is an insulin presented as a solution for injection, prefilled pen for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients by providing basal and prandial insulin coverage.

GNH India supplies Mixtard 30 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novo Nordisk A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mixtard 30 Penfill is a human insulin used in the management of diabetes mellitus, providing both basal and mealtime glucose control.

  • Type 1 diabetes mellitus: improves overall glycemic control by replacing deficient endogenous insulin.
  • Type 2 diabetes mellitus: assists in achieving target blood glucose when oral agents are insufficient.
  • Diabetes mellitus (any type): offers combined basal and rapid‑acting insulin action for flexible dosing.

How It Works

  • Insulin human binds to insulin receptors on cell membranes, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling pathways that promote glucose uptake in muscle and adipose tissue, suppress hepatic glucose production, and facilitate glycogen synthesis, thereby lowering circulating blood glucose levels.

Side Effects

Mixtard 30 Penfill may be associated with a range of adverse reactions.

Common Side Effects

  • Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: increased caloric storage due to improved glucose utilization.
  • Lipodystrophy: localized fat accumulation or loss at injection sites.
  • Edema: mild peripheral swelling.
  • Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects

  • Severe hypoglycemia: neurological impairment requiring immediate assistance.
  • Allergic reaction or anaphylaxis: rash, itching, swelling, or difficulty breathing.
  • Insulin antibodies: may alter insulin effectiveness.
  • Diabetic ketoacidosis: rare if insulin dose is insufficient or abruptly stopped.

Precautions & Warnings

When using Mixtard 30 Penfill, several safety considerations should be observed.

  • Blood glucose monitoring: check levels regularly to adjust dose as needed.
  • Hypoglycemia risk: avoid dosing when blood glucose is already low.
  • Illness or stress: may require temporary dose adjustments.
  • Renal or hepatic impairment: use with caution and monitor glucose closely.
  • Pregnancy and lactation: safety not fully established; consult a healthcare professional.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insulin may interact with other medicines, altering its glucose‑lowering effect.

Major Interactions (Avoid)

  • Beta‑blockers: can mask symptoms of hypoglycemia.
  • Sulfonylureas and meglitinides: increase risk of severe hypoglycemia.
  • ACE inhibitors: may potentiate insulin’s glucose‑lowering action.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: raise blood glucose, possibly requiring higher insulin doses.
  • Thiazide diuretics: may increase glucose levels.
  • Oral contraceptives: can affect insulin sensitivity and glucose control.

Frequently Asked Questions

Mixtard 30 Penfill is a prefilled insulin pen that provides human insulin for the treatment of type 1 and type 2 diabetes mellitus. It supplies both basal and rapid‑acting insulin to help patients achieve stable blood glucose levels as part of a comprehensive diabetes management plan.

Insulin human binds to insulin receptors on muscle, fat, and liver cells, activating intracellular pathways that increase glucose uptake, reduce hepatic glucose production, and promote glycogen storage. These actions collectively lower circulating blood glucose and provide energy to cells.

The dose of Mixtard 30 Penfill is individualized. A qualified prescriber determines the appropriate amount based on the patient’s blood glucose readings, dietary intake, activity level, and overall treatment goals. Patients should follow the prescribing clinician’s instructions exactly.

Safety data for insulin human in pregnancy and lactation are limited. Healthcare providers may prescribe it when the benefits outweigh potential risks, but the decision should be made in consultation with a obstetrician or maternal‑fetal medicine specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Mixtard 30 Penfill contains human insulin, offering a blend of rapid‑acting and intermediate‑acting components in a single pen. Compared with rapid‑acting analogues, it may have a slightly longer onset but provides both basal and prandial coverage, reducing the number of injections for some patients.

Store Mixtard 30 Penfill at 2‑8 °C (refrigerated) and protect it from light. Do not freeze or shake the pen. Once in use, the pen may be kept at room temperature for up to 28 days, but it should be discarded after that period.

Mixtard 30 Penfill is administered subcutaneously using the prefilled pen. The injection site can be the abdomen, thigh, or upper arm. Patients should rotate injection sites to reduce the risk of lipodystrophy and follow the pen’s dosing instructions provided by their healthcare professional.

The most serious risks include severe hypoglycemia, which can cause confusion, loss of consciousness, or seizures, and allergic reactions that may lead to anaphylaxis. Prompt recognition and treatment are essential, and patients should be educated on recognizing early signs.

Mixtard 30 Penfill should be avoided in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia until glucose levels are corrected.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT